About this trial
Cerebrovascular diseases pose a major global public health challenge, characterized by exceptionally high mortality and disability rates, with their pathogenesis closely linked to hemodynamic abnormalities. The quantitative digital subtraction angiography (QDSA) analysis platform, leveraging its advantages of vessel modeling-free operation, high computational efficiency, and DSA-equivalent sensitivity, has emerged as a novel hemodynamic assessment method with significant clinical potential. This study aims to establish a cerebrovascular disease cohort incorporating QDSA parameters to systematically validate the clinical value of this technology in preoperative evaluation and surgical planning, thereby providing evidence-based insights for optimizing diagnostic and therapeutic strategies.
Eligibility criteria
Qualifiers
Cerebrovascular diseases diagnosed and assessed by DSA for related risks and treatment options.
The DSA acquisition protocol complies with the standard procedure.
DSA images must include complete anteroposterior and lateral views.
Raw data must be available in DICOM format.
Disqualifiers
Cerebrovascular diseases not diagnosed or risk-assessed using DSA.
Patients with DSA image quality insufficient for image analysis and processing.
Severe organ diseases with an expected survival period of less than 2 years.
Inability to cooperate with treatment and follow-up.
Trial design
Treatments tested in this trial
- QDSA (Quantitative Digital Subtraction Angiography)